WARMINSTER, Pa., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following investor conference:
H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference: Formal Presentation on October 25, 2023 at 4:30 pm ET
To access the live webcast of the presentation please ...